ROIV
Roivant Sciences Ltd.
Pharmaceutical Preparations- 売上
- $8m
- 時価総額
- $23.5bn
株価 $34.52 · 100株 3,452円
| 期 | 24/03 | 25/03 | 26/03 |
|---|---|---|---|
| 売上 | $33m | $29m | $8m |
| 成長率 | — | ▲11.2% | ▲71.6% |
| 総利益 | — | — | — |
| 総利益率 | — | — | — |
| 販管費 | $416m | $591m | $610m |
| 販管費率 | 1,272.1% | 2,035.6% | 7,390.6% |
| 営利 | $4.5bn | ▲$1.0bn | ▲$515m |
| 営利率 | 13,746.9% | ▲3,453.3% | ▲6,235.7% |
| 純利益 | $4.3bn | ▲$172m | ▲$300m |
| PBR | 3.9 | 5.0 | 5.2 |
| PSR | 717.4 | 807.7 | 2,841.0 |
| PGPR | — | — | — |
| PER | 5 | — | — |
| ﾈｯﾄｷｬｯｼｭ | $6.0bn | $2.3bn | $971m |
| EV/EBITDA | 3.9 | — | — |
| Rule of 40 | — | ▲3,465% | ▲6,307% |
| セールス効率 | — | — | — |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）